Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5
Inhibikase Therapeutics Inc IKT
$1.83
▲ +8.93%
(+$0.15)
Open
$1.72
Prev Close
$1.68
Day Range
$1.71 – $1.83
52W Range
$1.33 – $2.26
Market Cap
$241.62M
Beta
1.00
EPS (TTM)
$-1.15
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-12-23 |
| Shares Out. | 132,030,000 |
| Website | inhibikase.com/ ↗ |
| Phone | 13022953800 |
Inhibikase Therapeutics Inc is a publicly traded company under the ticker symbol IKT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-06-01)